<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928991</url>
  </required_header>
  <id_info>
    <org_study_id>14-011465</org_study_id>
    <secondary_id>14BT057</secondary_id>
    <nct_id>NCT02928991</nct_id>
  </id_info>
  <brief_title>Fludarabine Based RIC for Bone Marrow Failure Syndromes</brief_title>
  <official_title>Fludarabine-Based Conditioning for Matched Related Donor Bone Marrow Transplantation in Patients With Bone Marrow Failure Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to determine whether fludarabine-based reduced intensity conditioning&#xD;
      (RIC) regimens facilitate successful donor engraftment of patients with acquired aplastic&#xD;
      anemia (AA) and Inherited bone marrow failure (iBMF) syndromes undergoing Matched related&#xD;
      donor bone marrow transplant (MRD-BMT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acquired AA patients will receive the experimental regimen of fludarabine with dose-reduced&#xD;
      cyclophosphamide, with results in this prospective single arm experimental group evaluated in&#xD;
      the context of our institutional historical experience using HD Cy regimens as well as&#xD;
      published outcomes using both fludarabine and high-dose cyclophosphamide-based regimens for&#xD;
      MRD-BMT in aplastic anemia. iBMF syndrome patients will receive one of two&#xD;
      fludarabine-containing regimens based on disease characteristics, and our outcomes will be&#xD;
      compared to previously published data using a variety of regimens. Graft versus host disease&#xD;
      (GvHD) prophylaxis will consist of cyclosporine/tacrolimus alone for patients with acquired&#xD;
      AA or cyclosporine/tacrolimus plus mycophenolate for patients with iBMF syndromes. For both&#xD;
      acquired AA and iBMF syndrome patients, donor chimerism will be assessed at scheduled&#xD;
      intervals following BMT and will be used to define patients with full donor or mixed&#xD;
      chimerism for comparisons of survival, graft failure, cytogenetic, GvHD, and immune&#xD;
      reconstitution outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of graft failure</measure>
    <time_frame>Up to 1 year post transplant</time_frame>
    <description>Combined rate of primary and secondary graft failure. Primary graft failure is defined as no evidence of neutrophil engraftment by day +28 after stem cell infusion. Secondary graft failure is defined as an ANC&lt;100 for &gt;7-10 days after initial engraftment occurs and is confirmed by hypocellular bone marrow biopsy and donor engraftment &lt;20%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>Up to 1 year post transplant</time_frame>
    <description>The time from the day of transplant until neutrophil engraftment, which is defined as the first day of ANC &gt;500/ul for the first of 3 consecutive days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transplant-related mortality</measure>
    <time_frame>Up to 100 days post transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of overall survival</measure>
    <time_frame>Up to 1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of disease free survival</measure>
    <time_frame>Up to 1 year post transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Bone Marrow Failure Syndromes</condition>
  <arm_group>
    <arm_group_label>Acquired Aplastic Anemia (AA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with severe or very severe acquired aplastic anemia (AA). Patients will receive a matched related donor bone marrow transplant following reduced intensity conditioning (RIC) including thymoglobulin (ATG), fludarabine and dose-reduced cyclophosphamide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inherited Bone Marrow Failure Syndrome + Trilineage Aplasia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with inherited bone marrow failure (iBMF) syndromes with trilineage aplasia includes those with diagnoses of Fanconi Anemia, Dyskeratosis Congenita, and related conditions. Patients will receive a matched related donor bone marrow transplant following conditioning with fludarabine, cyclophosphamide, thymoglobulin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inherited Bone Marrow Failure Syndrome no Trilineage Aplasia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with inherited bone marrow failure (iBMF) syndromes without trilineage aplasia includes those with diagnoses of Severe Congenital Neutropenia, Diamond-Blackfan Anemia, and related conditions. Patients will receive a matched related donor bone marrow transplant following conditioning with thymoglobulin, busulfan and fludarabine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRD-BMT with Fludarabine-based RIC for Acquired AA</intervention_name>
    <description>Fludarabine: Dose: 30mg/m2/day (&lt;10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3&#xD;
Cyclophosphamide: Dose: 60mg/kg/day Days: -5, -4&#xD;
Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2&#xD;
Bone marrow infusion: Day 0</description>
    <arm_group_label>Acquired Aplastic Anemia (AA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia</intervention_name>
    <description>Fludarabine: Dose: 30mg/m2/day (&lt;10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3&#xD;
Cyclophosphamide: Dose: 10 mg/kg/day Days: -6, -5, -4, -3&#xD;
Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2&#xD;
Bone marrow infusion: Day 0</description>
    <arm_group_label>Inherited Bone Marrow Failure Syndrome + Trilineage Aplasia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia</intervention_name>
    <description>Fludarabine: Dose: 30mg/m2/day (&lt;10kg will receive 1mg/kg/day) Days: -6, -5, -4, -3, -2&#xD;
Busulfan: Dose: every 6 hours for a total of 12 doses with dosing adjustments to achieve a steady state concentration of 900-1200ng/mL OR daily for a total of 3 doses targeting AUC 3600-6000 (micromole/liter)*minute Days: -7, -6, -5, -4&#xD;
Thymoglobulin: Dose: 3mg/kg/day Days: -10, -9, -8&#xD;
Bone marrow infusion: Day 0</description>
    <arm_group_label>Inherited Bone Marrow Failure Syndrome no Trilineage Aplasia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients 0-22 years with acquired aplastic anemia or a diagnosed inherited bone marrow&#xD;
        failure syndrome, and a fully Human leukocyte antigen (HLA)-matched (10/10) related donor.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        Patient:&#xD;
&#xD;
          1. Ages 0-22 years at time of enrollment&#xD;
&#xD;
          2. Diseases:&#xD;
&#xD;
               -  Patients with severe or very severe acquired AA, defined by:&#xD;
&#xD;
                    -  Bone marrow biopsy demonstrating cellularity of &lt;25% (at least 2 weeks from&#xD;
                       last dose of G-CSF), in addition to 2 of the following: absolute neutrophil&#xD;
                       count (ANC) &lt;500/µL, platelets &lt; 20,000/µL and absolute reticulocytes&#xD;
                       &lt;40,000/µL&#xD;
&#xD;
                    -  Negative evaluation for inherited bone marrow failure conditions and&#xD;
                       negative evaluation for dysplasia or cytogenetic abnormalities associated&#xD;
                       with myelodysplastic syndromes&#xD;
&#xD;
                    -  Patients with concurrent paroxysmal nocturnal hemoglobinuria (PNH) clones&#xD;
                       are eligible, as long as they meet criteria for severe or very severe&#xD;
                       aplastic anemia as defined above&#xD;
&#xD;
               -  Patients with clinically diagnosed and/or genetically proven iBMF syndromes,&#xD;
                  resulting in chronic red blood cell or platelet-transfusion dependence and/or an&#xD;
                  absolute neutrophil count &lt;500/µL. These disorders include, but are not limited&#xD;
                  to:&#xD;
&#xD;
                    -  Fanconi Anemia&#xD;
&#xD;
                    -  Dyskeratosis Congenita&#xD;
&#xD;
                    -  Severe Congenital Neutropenia&#xD;
&#xD;
                    -  Diamond-Blackfan Anemia&#xD;
&#xD;
                    -  Congenital Dyserythropoietic/Sideroblastic Anemias&#xD;
&#xD;
                    -  Congenital Amegakaryocytic Thrombocytopenia&#xD;
&#xD;
                    -  Shwachman-Diamond Syndrome&#xD;
&#xD;
          3. Lansky or Karnofsky performance &gt;60&#xD;
&#xD;
          4. HLA matched related donor available.&#xD;
&#xD;
          5. No active untreated infection&#xD;
&#xD;
          6. Females of childbearing potential must have negative pregnancy test.&#xD;
&#xD;
        Organ Function:&#xD;
&#xD;
          -  Serum creatinine &lt;1.5xupper limit of normal for age Hepatic: Transaminases &lt;5x normal&#xD;
&#xD;
          -  Cardiac shortening fraction &gt;27%&#xD;
&#xD;
          -  Bilirubin &lt;2.5x normal (unless elevation due to Gilberts disease).&#xD;
&#xD;
        Donor Selection Criteria:&#xD;
&#xD;
          -  Donor selection will comply with U.S. Food and Drug Administration's Code of Federal&#xD;
             Regulations&#xD;
&#xD;
          -  Fully HLA-matched related donor.&#xD;
&#xD;
          -  Donor must be at least 6 months of age&#xD;
&#xD;
          -  Donor suitable for bone marrow collection and meets eligibility for donation,&#xD;
             including fulfilling infectious disease criteria as per SOP, including HIV, Hepatitis&#xD;
             B, Hepatitis C Polymerase chain reaction (PCR) negative.&#xD;
&#xD;
          -  If subject has confirmed iBMF syndrome, donor must be evaluated for this disorder and&#xD;
             testing must be negative&#xD;
&#xD;
          -  Children's Hospital of Philadelphia (CHOP) bone marrow transplant (BMT) procedures&#xD;
             apply for determining donor eligibility, including donor screening and testing for&#xD;
             relevant communicable disease agents and diseases.&#xD;
&#xD;
          -  Donor evaluation and collection procedure as per CHOP Standard Operating Procedures&#xD;
             (SOP)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled bacterial, viral or fungal infections&#xD;
&#xD;
          -  HLA matched related donor unable to donate bone marrow.&#xD;
&#xD;
          -  No eligible fully HLA-matched related donor&#xD;
&#xD;
          -  Pregnant females&#xD;
&#xD;
          -  Patients with a clinical diagnosis of Myelodysplastic syndrome (MDS) defined by&#xD;
             combination of bone marrow dysplasia and classic cytogenetic lesion (Monosomy 7,&#xD;
             Trisomy 8 eg.), with or without excess blasts.&#xD;
&#xD;
          -  Patients with PNH without underlying bone marrow aplasia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Olson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Timothy Olson, MD, PhD</last_name>
    <email>OLSONT@chop.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Olson, MD, PhD</last_name>
      <email>OLSONT@chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Barbara McGlynn, RN, BSN</last_name>
      <email>MCGLYNN@chop.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Timothy Olson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2016</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Philadelphia</investigator_affiliation>
    <investigator_full_name>Timothy Olson</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Acquired aplastic anemia</keyword>
  <keyword>Inherited bone marrow failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Marrow Failure Disorders</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

